During 2006 and early 2007 two new drugs, sunitinib and sorafenib, were licensed in Europe for the treatment of metastatic renal cell cancer. Both of these agents have been shown to produce significant clinical benefit and prolong progression-free survival (PFS) in patients who have received previous cytokine therapy [1, 2] . One of them, sunitinib, is superior to interferon (IFN) in previously untreated patients [3] . As well as these two agents a number of other targeted agents, including temsirolimus and bevacizumab [4, 5] , are showing encouraging results in clinical trials and may well be licensed within the foreseeable future. These new treatments represent the most significant advance in the treatment of metastatic renal cell cancer in 30 years. Therefore, the question to be asked is 'Do these drugs make immunotherapy redundant?'.
immunotherapy interleukin-2
Interleukin-2 (IL-2) entered clinical trials in the mid-1980s. In the USA, Rosenberg developed a high-dose bolus programme (BIV) in patients with metastatic renal cell cancer. This treatment is still the only Food and Drug Administration (FDA)-approved IL-2-based therapy in the USA. It produces responses in 20% of patients with a median duration of response of 54 months. The median survival of the 8% of patients that achieve a complete response (CR) has not yet been reached and 60% of these patients are alive at a median follow-up of >10 years [6] . This treatment is, however, very challenging for both patients and physicians, requiring high dependency or intensive care support due to capillary leak syndrome [7] .
Because of the challenging nature of high-dose BIV treatment, the cytokine working group conducted a trial comparing the original high-dose BIV regimen with a lowdose bolus treatment (LDIV) [8] . In this trial a total of 156 patients were randomly assigned to BIV IL-2, and 150 patients to LDIV IL-2. Toxicities were less frequent with LDIV IL-2 (especially hypotension), but there were no IL-2-related deaths in either arm. There was a higher response rate with BIV IL-2 (21%) versus LDIV IL-2 (13%; P = 0.048) but no overall survival difference.
The response rate of subcutaneous IL-2 (10%, partial and complete response) was similar to that of LDIV IL-2, but different from BIV (P = 0.033). Response duration and survival in completely responding patients was superior with BIV compared with LDIV therapy (P = 0.04).
These data suggest that BIV IL-2 should be offered to patients with a good performance status because it offers the highest chance. Reliable predictive markers of response and survival would be of great value in this setting.
Recently, Atkins and colleagues [9] examined the relationship between positive staining of the renal cell carcinoma for carbonic anhydrase IX (CAIX) and outcome in 66 patients who had received HDIV IL-2. 78% of the responders had high CAIX staining compared with only 51% of the non-responders. Survival beyond 5 years was only seen in patients with high CAIX staining and the survival curve had a plateau at around 40% beyond 5 years. These authors have proposed a model incorporating a predictive pathological model developed by Upton and colleagues [10] and CAIX staining (Table 1) . Based on this model, one could certainly recommend high-dose IL-2 for the patients in the good-risk group because their chance of response is 26/44 (59%) with excellent prospects of long-term survival and the possibility of cure.
interferon Recombinant IFNs were introduced into the clinic at the beginning of the 1980s. Overall, $15% of patients will respond to INF [11] . However, complete remissions are rare. The median duration of response and survival are 6 and 15 months, respectively. A Cochrane meta-analysis summarizing data from trials comparing IFN with control showed significant benefit for interferon in terms of response (odds ratio 4.89, P = <0.0001) and survival at 1 year [relative reduction is risk of death (RR) 0.67, P = 0.007] [12] .
It is possible to select patients who will have a relatively good outcome when treated with IFN [13] . The model was based on 670 patients treated with first-line INF at the Memorial Sloan Kettering Cancer Center (MSK). The model was then validated on an independent data set from Eastern Cooperative Oncology Group (ECOG) trials consisting of 175 patients. The results are shown in Table 2 . The five factors that independently predicted median survival were Karnofsky performance status <80%, high lactate dehydrogenase (LDH) (>1.5 Á upper limit of normal), low haemoglobin (<lower limit of normal), high serum calcium (>10 mg/dl) and no prior nephrectomy. This model was also validated with data from the Cleveland Clinic [14] .
The pivotal trial [3] comparing IFN with sunitinib included 143 and 121 with zero prognostic factors in the two arms, respectively. The authors state that the performance status has not been reached for patients given sunitinib whilst it was 8 months those receiving IFN. No survival data were reported for the favourable risk group. Since sunitinib has been demonstrated to produce good tumour control rates after cytokine failure, the optimum long-term strategy in the favourable-risk patients may still be to give IFN first and sunitinib after it fails. It is unclear what the efficacy of IFN will be after sunitinib failure. Long and careful follow-up of patients in this trial may give clues as to the optimum sequencing of treatments. It is very likely that patients who respond initially to IFN will be given sunitinib at treatment failure. It is less likely that those who fail initial sunitinib will receive IFN. If the long-term survival of those who received and responded to IFN and later were treated with sunitinib turns out to be longer than those patients who never received IFN this would be circumstantial evidence in favour of an IFN followed by sunitinib strategy. Certainly in the groups of patients with less favourable prognostic factors for survival with IFN therapy, sunitinib should now be the treatment of choice as factors that predict a beneficial effect for IFN do not seem to apply to patients receiving sunitinib.
transplantation
The realization that the therapeutic effects of allogeneic bone marrow and stem cell transplantation in haematological malignancies was mediated through a graft-versus-tumour effect, led the way to the development of non-myelo-ablative conditioning regimen which has greatly reduced the morbidity and mortality associated with these procedures. This frameshift opened the door to studies of this form of immunotherapy in patients with solid tumours. There have now been 12 reports [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] of non-myelo-ablative transplant studies in patients with metastatic renal cell cancer.
An excellent overview of this strategy has been published by Yang and Childs [26] . The results are summarized in Table 3 . The largest series was that reported by Barkholt and colleagues [26] from the European Bone Marrow transplant registry and probably gives the truest reflection of the efficacy of this approach. Differences between the studies are likely to be due to the heterogeneity of patients treated as well as to differences in the conditioning and immunosuppressive regimens. Treatment-related mortality was 16% in this series. The development of graft-versus-host disease correlates strongly with the probability of response.
Because of this, physicians have to walk a fine line between giving the patient the optimum chance of responding to the therapy without causing increased risk of treatment-related death due to graft-versus-host disease.
vascular endothelial growth factor
In order for immune effector cells to kill tumour cells they must gain access to the tumour stroma from the blood. It has recently been demonstrated that tumour endothelium has down-regulated the adhesion molecules which are necessary to allow immune effectors to adhere to endothelium which is the first step in the diepidesis process [27, 28] . This so-called endothelial anergy can be reversed by inhibiting the vascular endothelial growth factor (VEGF) pathway. These observations suggest that combining anti-VEGF agents such as bevacizumab or sunitinib/sorafenib may enhance the effects of immunotherapy. This concept should be explored in clinical trials.
tumour vaccines
Nine studies of tumour vaccines have been reported in metastatic renal cancer patients [29] [30] [31] [32] [33] [34] [35] [36] [37] . The number of [26] 124 16 32 patients included in these trials has been small and there have been few responses. As mentioned above, even if vaccines generate sufficient numbers of anti-tumour effector cells these cells may not be able to enter tumour stroma because of endothelial cell anergy. Combining vaccines with anti-angiogenic agents might overcome this problem.
conclusion
It is very likely that immunotherapy will continue to be an important treatment modality in selected patients with metastatic renal cell cancer. It is very good news that we now have an increasing number of effective new agents for patients with this disease. The challenge in coming years will be to learn how to fit all the pieces of the jigsaw together in order to determine to optimal treatment algorithm for managing these patients.
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